Clinical Progress

Decoding Infigratinib: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GU

23 February 2024
4 min read

In the subset of patients with UC bearing alterations in the fibroblast growth factor 3 (FGFR3) gene, targeted therapies directed at this moiety have shown substantial antitumor effect in the metastatic setting. The 2024 ASCO_GU reported the latest clinical trial results of infigratinib, a potent and selective inhibitor of FGFR3, illustrating its potential clinical benefits. 

Infigratinib's R&D Progress

Infigratinib is a small molecule drug that targets FGFR1, FGFR2, FGFR3, and FGFR4. The drug has shown potential therapeutic applications in various areas of biomedicine. These include neoplasms (abnormal growth of cells), congenital disorders (conditions present at birth), endocrinology and metabolic diseases, skin and musculoskeletal diseases, digestive system disorders, and nervous system diseases. 

According to the Patsnap Synapse, Infigratinib is being developed by QED Therapeutics, Inc. and has reached the highest phase of clinical development, Phase 3, globally. In China, it has reached Phase 2. And the clinical trial distributions for Infigratinib are primarily in the United States, China and United Kingdom. The key indication is Advanced Malignant Solid Neoplasm. 

Detailed Clinical Result of Infigratinib

This randomized, parallel Assignment, Quadruple-blind clinical trial (NCT04197986) was aimed to evaluate the safety and efficacy of infigratinib as a adjuvant therapy in patients with high-risk resected UC.  

In this study, the authors randomly assigned patients in a 1:1 ratio to receive either oral infigratinib (125 mg) or placebo daily for 21 days of a 28-day treatment cycle, for a maximum of 13 cycles or until disease recurrence. Eligible patients had confirmed invasive UC with susceptible FGFR3 alterations and had undergone radical surgery within 120 days of randomization. The primary endpoint of the study was centrally assessed disease-free survival (DFS), with secondary endpoints including investigator-assessed DFS, metastasis-free survival (MFS) and overall survival (OS).

The result showed that despite intensive efforts to enroll approximately 218 patients (with 822 patients consented to molecular pre-screening), only 39 patients were enrolled with 20 and 19 patients randomized to receive infigratinib and placebo, respectively. The frequency of FGFR3 alteration was significantly lower than anticipated, occurring in only 19% of patients overall; mutations were observed in 13% of patients with lower tract UC and 30% of patients with upper tract UC. No significant differences were observed in DFS, MFS or OS, and more frequent grade 3/4 adverse events were noted in the experimental arm (35% versus 16%). No fatal adverse events were observed.

It can be concluded that the authors failure to accrue sufficient patients to the current trial precludes any definitive conclusions around the role of infigratinib as adjuvant therapy for FGFR3-altered UC. In the process of study conduct, however, we garnered substantial insights that may aid in the development of future precision oncology trials for adjuvant UC.

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Bayer Initiates Phase II Trial of New Anti-alpha2 Antiplasmin Drug for Deep Vein Thrombosis
Latest Hotspot
3 min read
Bayer Initiates Phase II Trial of New Anti-alpha2 Antiplasmin Drug for Deep Vein Thrombosis
23 February 2024
Bayer commences a second-stage trial using a novel anti-alpha2 antiplasmin agent in individuals affected by deep venous clots.
Read →
How to Effectively Search for BuSpar on Synapse
Drug Insights
2 min read
How to Effectively Search for BuSpar on Synapse
23 February 2024
BuSpar® (buspirone hydrochloride) is an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs.
Read →
EU Approves Pfizer's VELSIPITY® for Moderate to Severe Ulcerative Colitis
Latest Hotspot
3 min read
EU Approves Pfizer's VELSIPITY® for Moderate to Severe Ulcerative Colitis
23 February 2024
EU Regulatory Body Sanctions Pfizer's VELSIPITY® Use in Individuals with Moderate to Severe Ulcerative Colitis Cases.
Read →
Exploring Disitamab Vedotin's R&D successes and its clinical results at the 2024 ASCO_GU
Exploring Disitamab Vedotin's R&D successes and its clinical results at the 2024 ASCO_GU
23 February 2024
The latest ASCO_GU 2024 update summarized new clinical findings on disitamab vedotin and toripalimab as an innovative neoadjuvant therapy for HER2+ advanced local MIBC patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.